By Raul Valero, Beatriz Menéndez, Cristina Blanco Sánchez, Gonzalo García Domínguez, Natalia Canales, Rosalba Rosado, Ramon Menta Hernández, Maitane Ortiz-Virumbrales, Alvaro Avivar-Valderas, Laura M. Perez, Irene Zamora-Marmol, Eleuterio Lombardo, and Pablo Mancheño-Corvo
Volume 25, Open Access (May 2026)
The manufacturing of cell-based therapies requires harmonized processing protocols to ensure consistent quality. Expanded adipose-derived mesenchymal stromal cells (ASC) are among the most promising candidates for such therapies due to their regenerative and immunomodulatory properties. However, transitioning these therapies to large-scale production presents challenges related to cell recovery, formulation, and in-process cell counting (IPC). The Gibco CTS™ Rotea™ multipurpose Counterflow Centrifugation System enables multiple workflow operations—including cell separation, concentration, washing, and buffer exchange—and is designed to operate within a GMP environment. From a cell concentration perspective, the Rotea system can also formulate concentrated cells in different types of media, including fetal bovine serum…
Citation: Valero, R.; Menéndez, B.; Blanco Sánchez, C.; García Domínguez, G.; Canales, N.; Rosado, R.; Menta Hernández, R.; Ortiz-Virumbrales, M.; Avivar-Valderas, A.; Perez, L. M.; Zamora-Marmol, I.; Lombardo, E.; Mancheño-Corvo, P. Standardized and GMP-ready, closed-system processing of expanded adipose-derived stem cells using the Gibco CTS Rotea system across 2D and 3D bioreactor expansions. BioProcessing Journal 2026, 25. https://doi.org/10.12665/bioprocess.j.260512
Posted online May 12, 2026